Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

NCT02014740 on ClinicalTrials.gov · last registry update 2019-06-06

Finished March 2017, after enrolling 100 people. Primary outcome, as filed: Echocardiographic Epicardial Fat Thickness. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Miami
Sponsor type: Other
Enrollment: 100
Started: 2014-03
Primary completion: 2017-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Echocardiographic Epicardial Fat Thickness

Conditions studied

Type 2 Diabetes · Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.